Welcome, Friend!

It looks like you're new here. If you want to get involved, click one of these buttons!

Protect anonymity
We strongly suggest that members do not include their email addresses. Once that is published , your email address is available to anyone on the internet , including hackers.

All discussions and comments that contain an external URL will be automatically moved to the spam queue. No external URL pointing to a medical web site is permitted. Forum rules also indicate that you need prior moderator approval. If you are going to post an external URL, contact one of the moderators to get their approval.
There are no medical professionals on this forum side of the site. Therefore, no one is capable or permitted to provide any type of medical advice.
This includes any analysis, interpretation, or advice based on any diagnostic test

The main site has all the formal medical articles and videos for you to research on.

med suggested to be off market

StarshineSStarshine Posts: 68
edited 06/11/2012 - 7:48 AM in Pain Medications

If anyone is on this:

Propoxyphene Withdrawn From US Market

Allison Gandey

Authors and Disclosures

Posted: 11/19/2010
Nurse Rating: 5 stars ( 40 Votes )
Rate This Article:

0 stars

* Print This Print This
* Email This Email this
Facebook Twitter


Information from Industry
Build the practice of tomorrow--today?
The right team can deliver electronic health records (EHR) systems that meet the evolving needs of patient care.
Start modernizing today

November 19, 2010 — The US Food and Drug Administration (FDA) has asked that propoxyphene, sold under the brand names Darvon and Darvocet by Xanodyne Pharmaceuticals, be removed from the US market. The decision will also affect generic manufacturers and the makers of propoxyphene-containing products.

New clinical data showing that the drug puts patients at risk for potentially serious or even fatal heart rhythm abnormalities has prompted regulators to act. An estimated 10 million patients have used these products.

At a press conference today, John Jenkins, MD, director of the Office of New Drugs, said the new numbers tipped the risk–benefit ratio against the drug.
The withdrawal will include brand name, generic, and all propoxyphene-containing products.

"For the first time, we now have data showing that the standard therapeutic dose of propoxyphene can be harmful to the heart," said Gerald Dal Pan, MD, director of the Office of Surveillance and Epidemiology.

The FDA is advising healthcare professionals stop prescribing propoxyphene. Patients who are currently taking the drug should not abruptly halt their medication but should contact their physician as soon as possible to discuss switching to another pain-management therapy.

"Long-time users of the drug need to know that these changes to the heart's electrical activity are not cumulative," Dr. Dal Pan added. "Once patients stop taking propoxyphene, the risk will go away."

Propoxyphene is an opioid typically used to treat mild to moderate pain. It was first approved by the FDA in 1957. It is sold by prescription under various names alone or in combination with acetaminophen. Since 1978, the FDA has received 2 requests to remove propoxyphene from the market.

In January 2009, an FDA advisory committee voted 14 to 12 against the continued marketing of propoxyphene products. At that time, the committee called for additional information about the drug's cardiac effects.

Withdrawal Already Underway in Europe

A phased withdrawal of propoxyphene is already underway in Europe. The European Medicines Agency made that decision in June 2009. The FDA had considered a withdrawal last year but decided instead to allow continued marketing with a new boxed warning alerting patients and healthcare professionals of the risk for fatal overdose. The agency also required Xanodyne to conduct a new safety study assessing questions about the effects of propoxyphene on the heart.

The results of this study, combined with new epidemiologic data and medical examiner reports, prompted this latest regulatory action.

Should the FDA have acted sooner? Dr. Dal Pan told Medscape Medical News that regulators did not feel there was sufficient evidence before now. "The new information on the effects of the electrical activity on the heart was the final piece to the puzzle," he said.

"These new heart data significantly alter propoxyphene's risk–benefit profile," Dr. Jenkins added. "The drug's effectiveness in reducing pain is no longer enough to outweigh the drug's serious potential heart risks."
Authors and Disclosures
Allison Gandey

Allison Gandey is a journalist for Medscape. She is the former science affairs analyst for the Canadian Medical Association Journal. Allison, who has a master of journalism specializing in science from Carleton University, has edited a variety of medical association publications and has worked in radio and television. She can be contacted at agandey@webmd.net.

* Print This Print This
* Email This Email this
Facebook Twitter

More on This Topic

* Palliative Care in the Acute Care Setting (Emergency Medicine)
* Perioperative Pain Management in Newborns (Pediatrics: Cardiac Disease and Critical Care Medicine)
* Thoracic Discogenic Pain Syndrome (Sports Medicine)

* Adverse Drug Events Reporting Resource Center
* Pharmacologic Management of Pain Resource Center
* Back Pain Resource Center

Medscape Medical News © 2010 WebMD, LLC
Send press releases and comments to news@medscape.net.


  • Propoxyphene has few (if any) advantages and many disadvantages, so I'm not surprised it's being taken off the market. It was discontinued in the UK years ago. It's weaker than codeine and has been shown to have no more analgesic efficacy than APAP or aspirin.
  • The maker has agreed, Darvocet is officially off the market.

    Funny since we were just having this discussion on another thread! (eta: Nevermind, that was Demerol. Both D opiates, though!)
  • advertisement
Sign In or Register to comment.